Kisqali (ribociclib) is a targeted cancer medication indicated for the treatment of certain types of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
EGP 52,000
Kisqali (ribociclib) is a kinase inhibitor designed to slow the progression of breast cancer by inhibiting specific proteins that fuel cancer cell growth. This 600 mg daily dose regimen is provided in a convenient pack containing 63 film-coated tablets.
The product is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. As indicated in the packaging, the 600 mg daily dose consists of three 200 mg tablets taken daily.
It is essential to follow the dosage regimen precisely as prescribed by your oncologist. Please consult the enclosed Medication Guide for comprehensive instructions on administration and potential side effects.
